Valneva Corp - נכסים נקיים למניה בודדת VALN

Valneva SE (VALN) relies on a powerful staff of European virologists and experts, which eliminates the loss of key knowledge. Strong human capital supports the development of drugs for rare diseases, guaranteeing a steady cash flow and reliable working capital. This chart of current share prices demonstrates the asset's dynamics, where the indicator stands at 0.98. The company generates revenue from supplying vaccines to medical professionals, tourists, and government agencies to curb epidemics.

Analyzing an issuer's tangible assets is critical for constructing a defensive portfolio. This indicator is calculated by dividing total equity by the number of shares outstanding. For Valneva SE (VALN), the growth of this metric is supported by its monopoly position in the Chikungunya vaccination segment. Inelastic demand for unique pharmaceuticals directly capitalizes the organization's balance sheet. This price action is reflected in the current book value per share.